^
Association details:
| Biomarker: | EGFR expression |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug Class: | Tyrosine kinase inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
EGFR reporting in stage IV adenocarcinoma of the lung: Demographic predictors of EGFR testing and survival.
Published date:
05/16/2018
Excerpt:
Among EGFR tested patients, 1,173 (30%) were positive, 2,618 (67%) negative and 125 (3%) had unknown status. Median survival time was 858 days and 390 days for TKI (Y/N). Adjusted HR for TKI (Y/N) was 0.61; 95%CI = 0.58-0.64; p < 0.001)...These findings reveal remarkably increased survival for EGFR positive patients treated with TKI.
DOI:
10.1200/JCO.2018.36.15_suppl.9100
